These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 10629651)

  • 1. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.
    Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V
    Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
    Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
    J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
    Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients.
    Muley T; Dienemann H; Ebert W
    Anticancer Res; 2004; 24(3b):1953-6. PubMed ID: 15274383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
    Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
    Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC.
    Muley T; Dienemann H; Ebert W
    Anticancer Res; 2003; 23(5b):4085-93. PubMed ID: 14666606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
    Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
    Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group.
    Kulpa J; Wójcik E; Radkowski A; Kolodziejski L; Stasik Z
    Anticancer Res; 2000; 20(6D):5035-40. PubMed ID: 11326663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC.
    Muley T; Fetz TH; Dienemann H; Hoffmann H; Herth FJ; Meister M; Ebert W
    Lung Cancer; 2008 Jun; 60(3):408-15. PubMed ID: 18083270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
    Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
    Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer.
    Suzuki H; Ishikawa S; Satoh H; Ishikawa H; Sakai M; Yamamoto T; Onizuka M; Sakakibara Y
    Eur J Cardiothorac Surg; 2007 Oct; 32(4):648-52. PubMed ID: 17707649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of CYFRA 21-1 in non-small cell lung cancer.
    Hirashima T; Takada M; Komiya T; Nitta T; Masashi K; Masuda N; Matui K; Kikui M; Yasumitsu T; Kawase I
    Anticancer Res; 1998; 18(6B):4713-6. PubMed ID: 9891546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer.
    Tomita M; Shimizu T; Ayabe T; Yonei A; Onitsuka T
    Anticancer Res; 2010 Jul; 30(7):3099-102. PubMed ID: 20683062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21.1) immunoradiometric assay in non small cell lung cancer evaluation.
    Giovanella L; Ceriani L; Bandera M; Rimoldi R; Beghé B; Roncari G
    Q J Nucl Med; 1995 Dec; 39(4):285-9. PubMed ID: 8624791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of carcinoembryonic antigen in T1N1M0 and T2N1M0 non-small cell carcinoma of the lung.
    Fukai R; Sakao Y; Sakuraba M; Oh S; Shiomi K; Sonobe S; Saitoh Y; Miyamoto H
    Eur J Cardiothorac Surg; 2007 Sep; 32(3):440-4. PubMed ID: 17643308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy.
    Ebert W; Muley T
    Anticancer Res; 1999; 19(4A):2669-72. PubMed ID: 10470217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of serum cytokeratin 19 fragment and sialyl-Lewis x in non-small cell lung cancer.
    Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Kameyama M; Suehiro S
    Ann Thorac Surg; 2007 Jan; 83(1):216-21. PubMed ID: 17184666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
    Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
    Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.